Aarti Drugs Q2 FY27 Results: Consolidated Net Profit ₹82.77 Crore on Total Income of ₹829 Crore
- Earnings
- bulk drugs and chemicals
Reviewed byRachit TripathiBlacklitt Research
Aarti Drugs reported consolidated total income of ₹828.79 crore and net profit of ₹82.77 crore for the quarter ended 30 Sep 2026. Standalone net profit for the quarter was ₹57.68 crore. It said in a filing on 03 Nov 2026.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹828.79 crore, up 26.9% YoY and 17.8% QoQ
- Net profit and EPS: ₹82.77 crore, up 83.3% YoY; basic EPS ₹9.07 against ₹4.95
- Profit before tax: ₹109.28 crore, up 80.9% YoY
Standalone
The company on its own, without its subsidiaries
- Revenue from operations: ₹706.28 crore, up 22.0% YoY and 12.6% QoQ
- Net profit: ₹57.68 crore, up 38.1% YoY
- Profit before tax: ₹76.73 crore, up 37.6% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 829 | 653 | +26.9% | 704 | +17.8% | |
| Revenue from operations | 826 | 653 | +26.6% | 703 | +17.6% |
| 83 | 45 | +83.3% | 50 | +65.1% | |
| Profit before tax | 109 | 60 | +80.9% | 69 | +57.8% |
| Depreciation | 19 | 16 | +16.9% | 18 | +2.9% |
| Tax expense | 27 | 15 | +73.8% | 19 | +38.7% |
| Net profit margin | 9.99% | 6.92% | +3.07 pp | 7.12% | +2.86 pp |
| EPS, basic (₹) | 9.07 | 4.95 | +83.2% | 5.49 | +65.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit rose 83.3% year on year to ₹82.77 crore from ₹45.16 crore, while total income rose 26.9% to ₹828.79 crore from ₹652.88 crore. Consolidated net profit rose faster than total income.
Tax expense was ₹26.51 crore, 24.3% of profit before tax of ₹109.28 crore. A year earlier the tax expense was ₹15.25 crore on profit before tax of ₹60.41 crore.
For the half year ended 30 Sep 2026, consolidated revenue from operations was ₹1,529.03 crore against ₹1,243.30 crore for the half year a year earlier, up 23.0%.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 706 | 579 | +22.0% | 627 | +12.6% |
| 58 | 42 | +38.1% | 51 | +13.4% | |
| Profit before tax | 77 | 56 | +37.6% | 68 | +13.1% |
| Finance costs | 15 | n/a | n/a | n/a | n/a |
| Depreciation | 16 | n/a | n/a | n/a | n/a |
| Tax expense | 19 | 14 | +36.1% | 17 | +12.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone revenue from operations rose 22.0% year on year to ₹706.28 crore from ₹578.95 crore, and rose 12.6% quarter on quarter from ₹627.45 crore.
Standalone net profit rose 38.1% year on year to ₹57.68 crore from ₹41.78 crore. Standalone net profit rose faster than profit before tax (up 37.6%). Standalone tax expense of ₹19.05 crore was 24.8% of profit before tax of ₹76.73 crore.
For the half year ended 30 Sep 2026, standalone revenue from operations was ₹1,333.73 crore against ₹1,099.91 crore, up 21.3%, and standalone net profit was ₹108.53 crore against ₹90.42 crore, up 20.0%.
The company said it has one business segment, pharmaceuticals. The auditors, Gokhale & Sathe LLP, said they expressed an unmodified audit opinion on the quarter and half year results. For one foreign subsidiary the auditors relied on management-certified results, which management considers not material to the group.
Inference
The board approved the audited results at its meeting on 03 Nov 2026, and the company said it has arranged for them to be published in newspapers.
The filing does not say what drove the rise in profit.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
